Emerging Evidence for Glucagon-Like Peptide-1 Agonists in Slowing Chronic Kidney Disease Progression
Language
English
Publication Date
5-1-2024
Journal
Current Opinion in Nephrology and Hypertension
DOI
10.1097/MNH.0000000000000976
PMID
38411162
PMCID
PMC11126299
PubMedCentral® Posted Date
5-1-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
PURPOSE OF REVIEW: Diabetic kidney disease continues to increase, and several novel therapeutic agents have been shown to slow the progression of chronic kidney disease in those with diabetes. This review summarizes more recent data on the role of glucagon-like peptide-1 (GLP-1) receptor agonists and kidney outcomes.
RECENT FINDINGS: Posthoc analysis of cardiovascular outcome trials, as well as several retrospective studies, demonstrate benefits of GLP-1 receptor agonist therapy for chronic kidney disease progression in diabetics. Although limited randomized clinical trials evidence assessing the effects of GLP-1 receptor agonists on kidney outcomes in diabetic chronic kidney disease patients have been published, FLOW-CKD trial was halted based on interim data for efficacy, and results are awaited.
SUMMARY: GLP-1 receptor agonism is a promising therapy for slowing the progression of diabetic chronic kidney disease. Recent studies support kidney benefits GLP-1 receptor agonists over insulin and dipeptidyl peptidase-4-inhibitors, and the FLOW-CKD trial would inform the potential benefits for reducing the need for dialysis and kidney-disease related mortality in those with kidney disease.
Keywords
Humans, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Glucagon-Like Peptide 1, Hypoglycemic Agents, Randomized Controlled Trials as Topic, Renal Dialysis, Renal Insufficiency, Chronic, Retrospective Studies, Glucagon-Like Peptide-1 Receptor Agonists, diabetic kidney disease, GLP-1 receptor agonists, cardiovascular disease
Published Open-Access
yes
Recommended Citation
Michael W Holliday, Livia Frost, and Sankar D Navaneethan, "Emerging Evidence for Glucagon-Like Peptide-1 Agonists in Slowing Chronic Kidney Disease Progression" (2024). Faculty and Staff Publications. 4726.
https://digitalcommons.library.tmc.edu/baylor_docs/4726
Included in
Endocrinology, Diabetes, and Metabolism Commons, Health Services Research Commons, Medical Sciences Commons, Nephrology Commons